ProForma 2.0
Not calculated for this record
Back to Primary literature
Primary-literature peptidehigh evidence PepDiana evidence grade for a literature-derived identity; Medium indicates retained review flags, while High has no unresolved review flag.
PEPDIA-PLP-004213
tyroserleutide
Aliases: tyroserleutide
Normalized sequence
YSL
3 amino acids
Release PepDiana-V1-20260620
5
Activity records
1
Source papers
5
Positive
0
Negative / threshold
Cross-layer links
Related Integrated records
Versioned scientific descriptors
Physicochemical properties and standard representations
Reported properties
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Computed properties
physchem-20260620Molecular weight
Not calculated
Molecular formula
Not calculated
Theoretical pI
Not calculated
Net charge at pH 7
Not calculated
GRAVY
Not calculated
Instability index
Not calculated
Aromaticity
Not calculated
Topological polar surface area
Not calculated
cLogP
Not calculated
Hydrogen-bond donors
Not calculated
Hydrogen-bond acceptors
Not calculated
Rotatable bonds
Not calculated
Method: Not recorded
Tool: Not recorded
Calculated: Not recorded
Sequence representations
HELM 2.0
Not calculated for this record
Canonical SMILES
Not calculated for this record
Isomeric SMILES
Not calculated for this record
Paper-level observations
Experimental evidence grouped by activity
Anticancer 5 records
PMC12188416
5 observationsAnticancerPositive observation
Record detail YSL by itself exhibits limited anticancer activity, with an IC50 value of 4.34 mM (Figure S20).
- Measure
- other
- Value
- 4.34 mM
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerPositive observation
Record detail in the presence of 4.0 μM 5F–C12, the anticancer activity of YSL was remarkably potentiated, lowering the IC50 to 0.27 mM, corresponding to an improvement of 16.1-fold.
- Measure
- other
- Value
- 0.27 mM
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail YSL treatment resulted in moderate suppression of approximately 36.4%.
- Measure
- percent_inhibition
- Value
- approximately 36.4%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail In the YSL (8 mg/kg) + 5F–C12 (0.8 mg/kg) group, tumor inhibition increased markedly, reaching approximately 65.7% (Table S2).
- Measure
- percent_inhibition
- Value
- approximately 65.7%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail mice treated with YSL (8 mg/kg) combined with a higher dose of 5F–C12 (1.6 mg/kg) exhibited an even more pronounced tumor growth inhibition of 81.1% (Figure 6b,d).
- Measure
- percent_inhibition
- Value
- 81.1%
- Target
- MCF-7
- Assay
- Not reported by source
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-004213, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00